AJR Live Webinars feature leading experts discussing some of AJR’s most controversial, cutting-edge articles—broadcasted each month live, online, with CME.

Miss a broadcast? You can still watch past webinars and earn credit.

Past AJR Live Webinars

The AJR Live Webinar Series was made possible in part by an unrestricted educational grant from Siemens Healthcare. 

Upcoming Webinars

Author Interview: “Prospective Pilot Study of 18F-Fluoroestradiol PET/CT in Patients With Invasive Lobular Carcinomas”

June 21, 2023

Broadcasted Live and Online 12:00 noon–1:00 pm, Eastern Time 
Moderator: Heather Jacene
Speakers: Matt Covington, MD

Invasive lobular carcinoma is increasingly recognized as a distinct entity from the more common invasive ductal carcinoma and deserves dedicated research on detection and treatment strategies specific to this breast cancer sub-type. A 2020-2021 pilot study assessed the frequency with which sites of histologically proven ILC show abnormal uptake on FES PET/CT. Attendees will join corresponding author Matthew F. Covington, MD to discuss the study and its outcomes.

Register Now  

Learning Outcomes

Following the presentation, the participant should be able to:

  • Appreciate challenges in the imaging diagnosis of invasive lobular carcinoma.
  • Understand early data on use of FES-PET/CT for detection of histologically-proven sites of invasive lobular carcinoma.
  • Realize potential avenues of future research to advance the imaging detection of invasive lobular carcinoma using PET/CT imaging.

Hepatocellular Adenoma Subtypes Based on 2017 Classification System

July 19, 2023

Broadcasted Live and Online 12:00 noon–1:00 pm, Eastern Time 
Moderator: Federica Vernuccio, MD, PhD
Speakers: Justin R. Tse, MD

Hepatocellular adenomas (HCAs) are benign hepatocellular lesions that have the potential for hemorrhage and malignant transformation. Upon HCA diagnosis, lifestyle changes such as discontinuation of oral contraceptives as well as weight loss should be advised. Based on the most recent classification published in 2017, HCAs encompass eight subtypes of clonal benign hepatocellular proliferations on the basis of genetic and molecular analysis, each with clinical and management implications.

Authors of a study in the April 2023 issue of AJR will first discuss distinguishing qualitative and quantitative MRI features of HCAs based on gadoxetate disodium–enhanced MRI, stratified by subtype according to the 2017 genotypic classification of HCA. Then, they will propose a stepwise diagnostic algorithm for determining HCA subtype.

Register Now

Learning Outcomes

Following the presentation, the participant should be able to:

  • Understand how hepatocyte nuclear factor-1α mutated HCA usually demonstrates intralesional steatosis, absence of liver steatosis, hypointensity in the portal venous phase, and low signal intensity
    ratio across precontrast and all postcontrast phases.
  • The presence of atoll sign and moderate T2 hyperintensity is highly suggestive of inflammatory HCAs.
  • Findings more strongly associated with β-HCA and β-IHCA compared with the other subtypes included male sex, large size, hemorrhage, fluid components, and hepatobiliary phase iso- to hyperintensity.

    The American Roentgen Ray Society (ARRS) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education activities for physicians.

    The ARRS designates this live activity for a maximum of 1.00 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.